Special Issue "Automated Technology for Personalized Cancer Medicine: A Theme Issue in Honor of Prof. Dr. Thomas Grogan"
A special issue of Hemato (ISSN 2673-6357).
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 6534
Interests: microscope-based techniques; immunohistochemistry; immunofluorescence; antibodies; biomarkers; hematological malignancies; solid tumors; immuno-oncopathology; tumor microenvironment; immunotherapy
Interests: immunohistochemistry; in situ molecular techniques; brightfield in situ hybridization; virologic characterization; EBV; HHV8/KSHV; HPV; tumor microenvironment; Hodgkin’s lymphoma; HIV-associated lymphomas
This honorary issue celebrates Prof. Thomas Grogan, Emeritus Professor of Pathology at the University of Arizona and founder of Ventana Medical Systems Inc.
Prof Grogan’s scientific work was of great relevance in actively contributing to the development of the WHO classification of tumours of the hemopoietic and lymphoma tissues and his innovations in automated immunohistochemistry technology, as well as pre-analytical tissue processing, allowed him to develop several patents. The impact of these methodologies showed the clinical importance of cancer pathology, as they ensure reliable test results for determining patients’ treatment options. These advances, recognised by pathologists and clinical oncologists, further contributed to elevating the scientific importance of pathology.
We dedicate this honorary Special Issue to Prof. Tom Grogan, entitled "Automated Technology for Personalized Cancer Medicine", highlighting his major professional contributions, including novel development in the fields of immunohistology, in situ hybridization and clinical biomarkers.
The Special Issue will also focus on the impact of automated technologies on diagnostic and molecular pathology, as well as the identification of novel cancer therapies.
Prof. Dr. Teresa Marafioti
Prof. Dr. Annunziata Gloghini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- personalized cancer medicine
- cancer diagnosis
- automated technology
- lymphoma classification